Mitral transcatheter edge-to-edge repair vs. isolated mitral surgery for severe mitral regurgitation: a French nationwide study.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
14 Mar 2024
Historique:
received: 10 08 2023
revised: 21 12 2023
accepted: 17 01 2024
medline: 18 3 2024
pubmed: 20 1 2024
entrez: 20 1 2024
Statut: ppublish

Résumé

Mitral valve surgery and, more recently, mitral transcatheter edge-to-edge repair (TEER) are the two treatments of severe mitral regurgitation in eligible patients. Clinical comparison of both therapies remains limited by the number of patients analysed. The objective of this study was to analyse the outcomes of mitral TEER vs. isolated mitral valve surgery at a nationwide level in France. Based on the French administrative hospital discharge database, the study collected information for all consecutive patients treated for mitral regurgitation with isolated TEER or isolated mitral valve surgery between 2012 and 2022. Propensity score matching was used for the analysis of outcomes. A total of 57 030 patients were found in the database. After matching on baseline characteristics, 2160 patients were analysed in each arm. At 3-year follow-up, TEER was associated with significantly lower incidence of cardiovascular death (hazard ratio 0.685, 95% confidence interval 0.563-0.832; P = .0001), pacemaker implantation, and stroke. Non-cardiovascular death (hazard ratio 1.562, 95% confidence interval 1.238-1.971; P = .0002), recurrent pulmonary oedema, and cardiac arrest were more frequent after TEER. No significant differences between the two groups were observed regarding all-cause death (hazard ratio 0.967, 95% confidence interval 0.835-1.118; P = .65), endocarditis, major bleeding, atrial fibrillation, and myocardial infarction. Our results suggest that TEER for severe mitral regurgitation was associated with lower cardiovascular mortality than mitral surgery at long-term follow-up. Pacemaker implantation and stroke were less frequently observed after TEER.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Mitral valve surgery and, more recently, mitral transcatheter edge-to-edge repair (TEER) are the two treatments of severe mitral regurgitation in eligible patients. Clinical comparison of both therapies remains limited by the number of patients analysed. The objective of this study was to analyse the outcomes of mitral TEER vs. isolated mitral valve surgery at a nationwide level in France.
METHODS METHODS
Based on the French administrative hospital discharge database, the study collected information for all consecutive patients treated for mitral regurgitation with isolated TEER or isolated mitral valve surgery between 2012 and 2022. Propensity score matching was used for the analysis of outcomes.
RESULTS RESULTS
A total of 57 030 patients were found in the database. After matching on baseline characteristics, 2160 patients were analysed in each arm. At 3-year follow-up, TEER was associated with significantly lower incidence of cardiovascular death (hazard ratio 0.685, 95% confidence interval 0.563-0.832; P = .0001), pacemaker implantation, and stroke. Non-cardiovascular death (hazard ratio 1.562, 95% confidence interval 1.238-1.971; P = .0002), recurrent pulmonary oedema, and cardiac arrest were more frequent after TEER. No significant differences between the two groups were observed regarding all-cause death (hazard ratio 0.967, 95% confidence interval 0.835-1.118; P = .65), endocarditis, major bleeding, atrial fibrillation, and myocardial infarction.
CONCLUSIONS CONCLUSIONS
Our results suggest that TEER for severe mitral regurgitation was associated with lower cardiovascular mortality than mitral surgery at long-term follow-up. Pacemaker implantation and stroke were less frequently observed after TEER.

Identifiants

pubmed: 38243821
pii: 7577881
doi: 10.1093/eurheartj/ehae046
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

940-949

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Pierre Deharo (P)

Département de Cardiologie, CHU Timone, 264 rue Saint Pierre, 13005 Marseille, France.
Aix Marseille Univ, Inserm, Inra, C2VN, 264 rue Saint Pierre, 13005 Marseille, France.

Jean Francois Obadia (JF)

Hôpital Cardiovasculaire Louis Pradel, Chirurgie Cardio-Vasculaire et Transplantation Cardiaque, 28, Ave. Doyen Lépine, 69677 Bron CEDEX, France.

Patrice Guerin (P)

Service de Cardiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.

Thomas Cuisset (T)

Département de Cardiologie, CHU Timone, 264 rue Saint Pierre, 13005 Marseille, France.
Aix Marseille Univ, Inserm, Inra, C2VN, 264 rue Saint Pierre, 13005 Marseille, France.

Jean Francois Avierinos (JF)

Département de Cardiologie, CHU Timone, 264 rue Saint Pierre, 13005 Marseille, France.

Gilbert Habib (G)

Département de Cardiologie, CHU Timone, 264 rue Saint Pierre, 13005 Marseille, France.

Olivier Torras (O)

Département de Cardiologie, CHU Timone, 264 rue Saint Pierre, 13005 Marseille, France.

Arnaud Bisson (A)

Service de Cardiologie, Centre Hospitalier Trousseau, Tours, France.

Pascal Vigny (P)

Service d'information médicale, Unité d'épidémiologie hospitalière régionale, Université de Tours, 60 rue du plat d' Etain, 37000, France.

Christophe Saint Etienne (CS)

Service de Cardiologie, Centre Hospitalier Trousseau, Tours, France.

Carl Semaan (C)

Service de Cardiologie, Centre Hospitalier Trousseau, Tours, France.

Mickael Guglieri (M)

Service de Cardiologie, Centre Hospitalier Trousseau, Tours, France.

Nicolas Dumonteil (N)

Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France.

Frederic Collart (F)

Aix Marseille Univ, Inserm, Inra, C2VN, 264 rue Saint Pierre, 13005 Marseille, France.
Département de Chirurgie Cardiaque, CHU Timone, Marseille, France.

Martine Gilard (M)

Department of Cardiology, CHRU Brest, 29200 Brest, France.

Thomas Modine (T)

Département de Cardiologie, CHU Bordeaux, Bordeaux, France.

Erwan Donal (E)

CHU Rennes, Inserm, LTSI-UMR 1099, University of Rennes, F-35000 Rennes, France.

Bernard Iung (B)

AP-HP, Cardiology Department, Bichat Hospital, Université Paris Cité, INSERM 1148, Paris, France.

Laurent Fauchier (L)

Service de Cardiologie, Centre Hospitalier Trousseau, Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH